Emerging nanomedicine opportunities with perfluorocarbon nanoparticles
暂无分享,去创建一个
Shelton D Caruthers | Samuel A Wickline | Gregory M Lanza | Patrick M Winter | Kejia Cai | S. Caruthers | K. Cai | P. Winter | S. Wickline | G. Lanza
[1] T. Mekhail,et al. Paclitaxel in cancer therapy , 2002, Expert opinion on pharmacotherapy.
[2] S. Flaim. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.
[3] D. Curiel,et al. Cellular vehicles for cancer gene therapy: current status and future potential. , 2004, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[4] Andreas Saleh,et al. In vivo MRI of brain in ̄ ammation in human ischaemic stroke , 2004 .
[5] Samuel A Wickline,et al. Targeted ultrasonic contrast agents for molecular imaging and therapy. , 2001, Current problems in cardiology.
[6] Bartley P. Griffith,et al. Macrophage Accumulation Associated With Rat Cardiac Allograft Rejection Detected by Magnetic Resonance Imaging With Ultrasmall Superparamagnetic Iron Oxide Particles , 2001, Circulation.
[7] M. Brechbiel,et al. 3D‐micro‐MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties , 2001, Magnetic resonance in medicine.
[8] T. Lüscher,et al. Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications , 2006, Circulation.
[9] Mair Zamir,et al. Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteries. , 2003, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.
[10] Samuel A Wickline,et al. Targeted contrast agents for magnetic resonance imaging and ultrasound. , 2005, Current opinion in biotechnology.
[11] R E Jacobs,et al. Magnetic resonance microscopy of embryonic cell lineages and movements. , 1994, Science.
[12] S. Caruthers,et al. 1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles. , 2005, Current topics in developmental biology.
[13] D. Ingber,et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.
[14] Patrick Winter,et al. Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[15] J. Debatin,et al. Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic Rabbits , 2001, Circulation.
[16] Ergin Atalar,et al. In Vivo Magnetic Resonance Imaging of Mesenchymal Stem Cells in Myocardial Infarction , 2003, Circulation.
[17] Chien Ho,et al. Intracellular labeling of T‐cells with superparamagnetic contrast agents , 1993, Magnetic resonance in medicine.
[18] J. G. Miller,et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application. , 1996, Circulation.
[19] R. Mattrey. The potential role of perfluorochemicals (PFCs) in diagnostic imaging. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.
[20] Shelton D Caruthers,et al. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy , 2005, Expert review of cardiovascular therapy.
[21] M. Daemen,et al. Atherosclerotic plaque rupture: local or systemic process? , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[22] Sheng-Kwei Song,et al. High‐resolution MRI characterization of human thrombus using a novel fibrin‐targeted paramagnetic nanoparticle contrast agent , 2000, Magnetic resonance in medicine.
[23] K. Peters,et al. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. , 1998, American heart journal.
[24] S. Caruthers,et al. Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery. , 2004, Current pharmaceutical biotechnology.
[25] A. Sinusas,et al. Detection of Injury-Induced Vascular Remodeling by Targeting Activated &agr;vβ3 Integrin In Vivo , 2004 .
[26] P. Winter,et al. Improved Paramagnetic Chelate for Molecular Imaging with MRI , 2005 .
[27] Shelton D Caruthers,et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI , 2004, Magnetic resonance in medicine.
[28] Shelton D Caruthers,et al. Targeted magnetic resonance imaging contrast agents. , 2006, Methods in molecular medicine.
[29] M. E. Kooi,et al. Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging , 2003, Circulation.
[30] L. Naldini,et al. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. , 2006, Biochimica et biophysica acta.
[31] E T Ahrens,et al. Receptor‐mediated endocytosis of iron‐oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging , 2003, Magnetic resonance in medicine.
[32] Qingbo Xu,et al. The molecular mechanisms of vascular restenosis: Which genes are crucial? , 2006, Current vascular pharmacology.
[33] E J Topol,et al. Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. , 1996, Circulation.
[34] Shelton D Caruthers,et al. In Vitro Demonstration Using 19F Magnetic Resonance to Augment Molecular Imaging With Paramagnetic Perfluorocarbon Nanoparticles at 1.5 Tesla , 2006, Investigative radiology.
[35] Scott E. Fraser,et al. Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study , 2004, NeuroImage.
[36] M. Bock,et al. High‐resolution three‐dimensional MR angiography of rodent tumors: Morphologic characterization of intratumoral vasculature , 2003, Journal of magnetic resonance imaging : JMRI.
[37] S A Wickline,et al. Molecular imaging of stretch-induced tissue factor expression in carotid arteries with intravascular ultrasound. , 2000, Investigative radiology.
[38] M. Brechbiel,et al. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores , 2001, Magnetic resonance in medicine.
[39] David A. Cheresh,et al. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.
[40] Samuel A Wickline,et al. Nanotechnology for molecular imaging and targeted therapy. , 2003, Circulation.
[41] M. Reidy,et al. Kinetics of cellular proliferation after arterial injury. V. Role of acute distension in the induction of smooth muscle proliferation. , 1989, Laboratory investigation; a journal of technical methods and pathology.
[42] S. Robinson,et al. Design, synthesis, and evaluation of radiolabeled integrin αvβ3 receptor antagonists for tumor imaging and radiotherapy , 2003 .
[43] Shelton D Caruthers,et al. Molecular imaging of human thrombus with computed tomography. , 2005, Academic radiology.
[44] Samuel A Wickline,et al. Acoustic characterization in whole blood and plasma of site-targeted nanoparticle ultrasound contrast agent for molecular imaging. , 2005, The Journal of the Acoustical Society of America.
[45] T J Brady,et al. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. , 1992, Radiology.
[46] Juan J. Badimon,et al. Plaque Neovascularization Is Increased in Ruptured Atherosclerotic Lesions of Human Aorta: Implications for Plaque Vulnerability , 2004, Circulation.
[47] R. Müller,et al. Nanostructured lipid matrices for improved microencapsulation of drugs. , 2002, International journal of pharmaceutics.
[48] S. Fazel,et al. Current status of cellular therapy for ischemic heart disease. , 2005, The Annals of thoracic surgery.
[49] Samuel A Wickline,et al. Sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery. , 2005, Ultrasound in medicine & biology.
[50] E. Wu,et al. Mapping cyclic change of regional myocardial blood volume using steady‐state susceptibility effect of iron oxide nanoparticles , 2004, Journal of magnetic resonance imaging : JMRI.
[51] Eric T Ahrens,et al. In vivo imaging platform for tracking immunotherapeutic cells , 2005, Nature Biotechnology.
[52] D. Agrawal,et al. In stent restenosis: bane of the stent era , 2006, Journal of Clinical Pathology.
[53] R. Virmani,et al. Sustained Reduction of In-Stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel , 2002, Circulation.
[54] Samuel A Wickline,et al. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. , 2004, Magnetic resonance in medicine.
[55] M. Naghavi,et al. Superparamagnetic Iron Oxide–Based Method for Quantifying Recruitment of Monocytes to Mouse Atherosclerotic Lesions In Vivo: Enhancement by Tissue Necrosis Factor-&agr;, Interleukin-1&bgr;, and Interferon-&ggr; , 2003, Circulation.
[56] Samuel A Wickline,et al. Molecular imaging, targeted therapeutics, and nanoscience , 2002, Journal of cellular biochemistry. Supplement.
[57] M. Bednarski,et al. Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.
[58] H. Verheul,et al. Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. , 2006, Current pharmaceutical design.
[59] S. Caruthers,et al. Molecular imaging by MRI , 2006, Current cardiology reports.
[60] Grace Hu,et al. Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles , 2005, Magnetic resonance in medicine.
[61] A. C. van der Wal,et al. Tissue factor expression in the morphologic spectrum of vulnerable atherosclerotic plaques. , 2006, Seminars in thrombosis and hemostasis.
[62] K. Moulton. Plaque angiogenesis: its functions and regulation. , 2002, Cold Spring Harbor symposia on quantitative biology.
[63] F. Khuri,et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Stasia A. Anderson,et al. Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles , 2000 .
[65] Patrick J. Gaffney,et al. Quantitative “magnetic resonance immunohistochemistry” with ligand‐targeted 19F nanoparticles , 2004 .
[66] N. Ferrara,et al. Angiogenesis-Dependent and Independent Phases of Intimal Hyperplasia , 2004, Circulation.
[67] Kerry K. Karukstis,et al. Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.
[68] J. Werkmeister,et al. MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.
[69] J. Frank,et al. Cellular magnetic resonance imaging: current status and future prospects , 2006, Expert review of medical devices.
[70] J. G. Miller,et al. In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[71] S A Wickline,et al. Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.
[72] M A Konerding,et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.
[73] Samuel A. Wickline,et al. Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .
[74] S M Schwartz,et al. Angiogenesis in human coronary atherosclerotic plaques. , 1994, The American journal of pathology.
[75] Shelton D Caruthers,et al. Magnetic resonance molecular imaging with nanoparticles , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[76] Samuel A. Wickline,et al. Endothelial &agr;&ngr;&bgr;3 Integrin–Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis , 2006 .
[77] Sheng-Kwei Song,et al. Improved molecular imaging contrast agent for detection of human thrombus , 2003, Magnetic resonance in medicine.